Semaglutide vs Tesamorelin
Side-by-side comparison of Semaglutide, Tesamorelin — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss | Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | GLP-1 Receptor Agonist | GHRH Analogue |
| Amino acids | 31 | 44 |
| Molecular weight | 4,113.6 Da | 5,135.8 Da |
| Half-life | ~7 days | ~30 min |
| Route(s) | Subcutaneous injection, Oral (Rybelsus) | Subcutaneous |
| Mechanism & Research | ||
| Primary mechanism | Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… | Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its … |
| Research status | FDA Approved | FDA Approved |
| Evidence summary | Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… | Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s… |
| Protocol & Dosing | ||
| Typical dose | 0.25mg → 2.4mg weekly (weight management) | 2 mg/day |
| Frequency | Once weekly | Once daily |
| Duration | Ongoing (chronic management) | 26–52 weeks (clinical) |
| Timing | Same day each week, any time | Before breakfast or bedtime |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Tirzepatide, AOD-9604, Tesamorelin | CJC-1295, Sermorelin, AOD-9604 |
| Full profile | Read full Semaglutide profile → | Read full Tesamorelin profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.